e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2010
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
| Delaware
|
|
1-33734
|
|
94-3200380 |
|
|
|
|
|
|
| (State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
|
| 4939 Directors Place
|
|
92121 |
| San Diego, California
|
|
(Zip Code) |
| (Address of principal executive offices) |
|
|
Registrant’s telephone number, including area code: (858) 652-6500
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01. Regulation FD Disclosure
The Company has recently received and publicly announced certain clinical data related to its
products. A copy of the related press release is filed as Exhibit 99.1 to this Form 8-K and is
incorporated herein by reference in its entirety.
A copy of presentation materials describing the Company’s business used by the Company at a
scientific conference and investor presentations from time to time thereafter is filed as Exhibit
99.2 hereto. These materials reflect updates to information previously furnished by the Company
regarding the Company’s research and development programs, including information relating to
expected development milestones. The Company does not intend to file any update of these
presentation materials in the future. The fact that these updated presentation materials are being
furnished should not be deemed an admission as to the materiality of any information contained in
the materials.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
| |
|
|
|
|
| Exhibit |
|
|
|
| Number |
|
|
Document Description |
| 99.1 |
|
|
Press release dated November 8, 2010. |
| |
|
|
|
|
| 99.2 |
|
|
Ardea Biosciences, Inc. presentation materials date as
of November 8, 2010, and to be used from time to time
thereafter. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
|
|
|
|
| |
ARDEA BIOSCIENCES, INC.
|
|
| Date: November 8, 2010 |
/s/ CHRISTIAN WAAGE
|
|
| |
Christian Waage |
|
| |
General Counsel |
|
| |
EXHIBIT LIST
| |
|
|
|
|
| Exhibit |
|
|
| Number |
|
Document Description |
| |
99.1 |
|
|
Press release dated November 8, 2010. |
| |
|
|
|
|
| |
99.2 |
|
|
Ardea Biosciences, Inc. presentation materials updated
as of November 8, 2010, and to be used from time to
time thereafter. |